https://www.socictopen.socict.org/files/original/59e8e820a5a1087b2ece8b8c83acd8a7.pdf d8deb7aafc62f2f21056259f431fb97d Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update Creator An entity primarily responsible for making the resource Ravikant Kumar, Ashis K. Jha, Mahes K. Goenka, Vishwa M. Dayal Description An account of the resource Patients with novel coronavirus disease 2019 (COVID-19) are at significantly increased risk for mortality and morbidity. Current management remains supportive care, ranging from symptomatic outpatient management to full–intensive care support, including intravenous fluids, invasive, and non-invasive oxygen supplementation. In patients with septic shock, treatment with antibiotics and vasopressors are recommended to keep mean arterial pressure (MAP) ≥ 65 mm Hg and lactate < 2 mmol/L. Because of the lack of effectiveness and possible adverse effects, routine corticosteroids should be avoided unless they are indicated for another reason (exacerbation of asthma or chronic obstructive pulmonary disease [COPD], and septic shock in whom fluids and vasopressors do not restore hemodynamic stability). There is currently no sufficient evidence of efficacy of hydroxychloroquine/chloroquine, remdesivir, and other antivirals in the treatment or prevention of COVID-19. Limited evidence shows that COVID-19 convalescent plasma can be used as a treatment of COVID-19 without the occurrence of severe adverse events. Drug regulatory agencies granted an emergency-use authorization of chloroquine/hydroxychloroquine and remdesivir to treat patients when a clinical trial is not available or participation is not feasible. Chloroquine and hydroxychloroquine are associated with QT interval prolongation and life-threatening cardiac arrhythmia in patients with pre-existing cardiovascular disease. Guidelines are issued for use of convalescent plasma in patients with serious or immediately life-threatening COVID-19. Data from several ongoing randomized controlled trials will provide further evidence regarding the safety and efficacy of these drugs for the treatment of COVID-19. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource vaccines, chloroquine, World Health Organization, hydroxychloroquine, convalescent plasma, remdesivir, Severe Acute Respiratory Syndrome Coronavirus 2, novel coronavirus disease 2019 Identifier An unambiguous reference to the resource within a given context DOI: 10.1055/s-0040-1712547 Source A related resource from which the described resource is derived Journal of Digestive Endoscopy Publisher An entity responsible for making the resource available Thieme Publishers Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Diseases of the digestive system. Gastroenterology